Patents by Inventor Lawrence C. Madoff
Lawrence C. Madoff has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20030035805Abstract: The invention concerns a vaccine capable of protecting a recipient from infection caused group B Streptococcus. The vaccine comprises polysaccharide-protein moieties or protein moieties without a polysaccharide. The vaccine can contain, inter alia, (a) a group B Streptoccus polysaccharide conjugated to (b) either the N-terminal region of the epsilon antigen, a fragment thereof or their functional derivatives such that the vaccine retains the ability to elicit protective antibodies against group B Streptoccus. The vaccine may contain only one type of such polysaccharide-protein unit or may contain a mixture of more than one type of unit. Alternatively, the vaccine may contain antigens from different species of Group B Streptococcus. Additionally, the invention concerns a passive vaccine obtained following immunization with either the capsular polysaccharide-protein conjugate or the non-conjugated protein.Type: ApplicationFiled: April 30, 2002Publication date: February 20, 2003Applicant: The Brigham and Women's Hospital Inc.Inventors: James L. Michel, Lawrence C. Madoff, Dennis L. Kasper
-
Patent number: 6426074Abstract: The invention concerns a vaccine capable of protecting a recipient from infection caused group B Streptococcus. The vaccine comprises polysaccharide-protein moieties or protein moieties without a polysaccharide. The vaccine can contain, inter alia, (a) a group B Streptoccus polysaccharide conjugated to (b) either the N-terminal region of the epsilon antigen, a fragment thereof or their functional derivatives such that the vaccine retains the ability to elicit protective antibodies against group B Streptoccus. The vaccine may contain only one type of such polysaccharide-protein unit or may contain a mixture of more than one type of unit. Alternatively, the vaccine may contain antigens from different species of Group B Streptococcus. Additionally, the invention concerns a passive vaccine obtained following immunization with either the capsular polysaccharide-protein conjugate or the non-conjugated protein.Type: GrantFiled: March 18, 1998Date of Patent: July 30, 2002Assignee: The Brigham and Women's Hospital Inc.Inventors: James L. Michel, Lawrence C. Madoff, Dennis L. Kasper
-
Patent number: 6342223Abstract: A vaccine capable of protecting a recipient from infection caused by group B Streptococcus. The vaccine provides polysaccharide-protein moieties and contain (a) a group B Streptococcus polysaccharide conjugated to (b) a functional derivative of a group B Streptococcus C protein alpha antigen that retains the ability to elicit protective antibodies against group B Streptococcus. The vaccine may contain only one type of such polysaccharide-protein unit or may contain a mixture of more than one type of unit.Type: GrantFiled: July 20, 1999Date of Patent: January 29, 2002Assignee: The General Hospital Corporation & Brigham and Women's HospitalInventors: James L. Michel, Dennis L. Kasper, Frederick M. Ausubel, Lawrence C. Madoff
-
Patent number: 5968521Abstract: A vaccine capable of protecting a recipient from infection caused by group B Streptococcus. The vaccine provides polysaccharide-protein moieties and contain (a) a group B Streptococcus polysaccharide conjugated to (b) a functional derivative of a group B Streptococcus C protein alpha antigen that retains the ability to elicit protective antibodies against group B Streptococcus. The vaccine may contain only one type of such polysaccharide-protein unit or may contain a mixture of more than one type of unit.Type: GrantFiled: June 5, 1995Date of Patent: October 19, 1999Assignees: The General Hospital Corporation, Brigham and Women's HospitalInventors: James L. Michel, Dennis L. Kasper, Frederick M. Ausubel, Lawrence C. Madoff
-
Patent number: 5908629Abstract: A vaccine capable of protecting a recipient from infection caused by group B Streptococcus. The vaccine provides polysaccharide-protein moieties and contain (a) a group B Streptococcus polysaccharide conjugated to (b) a functional derivative of a group B Streptococcus C protein alpha antigen that retains the ability to elicit protective antibodies against group B Streptococcus. The vaccine may contain only one type of such polysaccharide-protein unit or may contain a mixture of more than one type of unit.Type: GrantFiled: June 6, 1995Date of Patent: June 1, 1999Assignees: The General Hospital Corporation, Brigham and Women's HospitalInventors: James L. Michel, Dennis L. Kasper, Frederick M. Ausubel, Lawrence C. Madoff
-
Patent number: 5858362Abstract: A vaccine capable of protecting a recipient from infection caused by group B Streptococcus. The vaccine provides polysaccharide-protein moieties and contain (a) a group B Streptococcus polysaccharide conjugated to (b) a functional derivative of a group B Streptococcus C protein alpha antigen that retains the ability to elicit protective antibodies against group B Streptococcus. The vaccine may contain only one type of such polysaccharide-protein unit or may contain a mixture of more than one type of unit.Type: GrantFiled: June 6, 1995Date of Patent: January 12, 1999Assignees: The General Hospital Corporation, Brigham and Women's HospitalInventors: James L. Michel, Dennis L. Kasper, Frederick M. Ausubel, Lawrence C. Madoff
-
Patent number: 5847081Abstract: A vaccine capable of protecting a recipient from infection caused by group B Streptococcus. The vaccine provides polysaccharide-protein moieties and contain (a) a group B Streptococcus polysaccharide conjugated to (b) a functional derivative of a group B Streptococcus C protein alpha antigen that retains the ability to elicit protective antibodies against group B Streptococcus. The vaccine may contain only one type of such polysaccharide-protein unit or may contain a mixture of more than one type of unit.Type: GrantFiled: June 5, 1995Date of Patent: December 8, 1998Assignees: The General Hospital Corp., The Brigham and Women's HospitalInventors: James L. Michel, Dennis L. Kasper, Frederick M. Ausubel, Lawrence C. Madoff
-
Patent number: 5843444Abstract: A vaccine capable of protecting a recipient from infection caused by group B Streptococcus. The vaccine provides polysaccharide-protein moieties and contain (a) a group B Streptococcus polysaccharide conjugated to (b) a functional derivative of a group B Streptococcus C protein alpha antigen that retains the ability to elicit protective antibodies against group B Streptococcus. The vaccine may contain only one type of such polysaccharide-protein unit or may contain a mixture of more than one type of unit.Type: GrantFiled: June 6, 1995Date of Patent: December 1, 1998Assignees: The General Hospital Corporation, Brigham and Women's HospitalInventors: James L. Michel, Dennis L. Kasper, Frederick M. Ausubel, Lawrence C. Madoff
-
Patent number: 5820860Abstract: A vaccine capable of protecting a recipient from infection caused by group B Streptococcus. The vaccine provides polysaccharide-protein moieties and contain (a) a group B Streptococcus polysaccharide conjugated to (b)) a functional derivative of a group B Streptococcus C protein alpha antigen that retains the ability to elicit protective antibodies against group B Streptococcus. The vaccine may contain only one type of such polysaccharide-protein unit or may contain a mixture of more than one type of unit.Type: GrantFiled: June 5, 1995Date of Patent: October 13, 1998Assignees: The General Hospital Corp., The Brigham and Women's HospitalInventors: James L. Michel, Dennis L. Kasper, Frederick M. Ausubel, Lawrence C. Madoff
-
Patent number: 5648241Abstract: A purified DNA molecule is disclosed that comprises a DNA sequence encoding a Group B Streptococcus alpha antigen or antibody eliciting fragment. The alpha antigen sequence encodes several distinct domains including an N-terminal sequence that precedes the start of the alpha antigen repeating sequence, a C-terminal anchor sequence and a repeating unit motif. The ability to protect mice against a Streptococcus infection with antisera against cellular extracts containing the alpha antigen encoded by the DNA molecule was determined.Type: GrantFiled: December 22, 1994Date of Patent: July 15, 1997Assignees: The General Hospital Corporation, Brigham and Women's HospitalInventors: James L. Michel, Dennis L. Kasper, Frederick M. Ausubel, Lawrence C. Madoff